Oxford BioDynamics EpiSwitch CIRT
Oxford BioDynamics has launched EpiSwitch CIRT, its checkpoint inhibitor response test, in the US. The blood-based test, which is based on the firm's EpiSwitch 3D genomics platform, is for predicting patient response to immune checkpoint inhibitors, including anti-PD-L1 and anti-PD-1 immunotherapies. According to the company, the qPCR test has demonstrated 93 percent sensitivity and 82 percent specificity across several immune checkpoint inhibitors from several drug firms and more than 15 oncological indications.
Sophia Genetics DDM Homologous Recombination Deficiency Detection App
Sophia Genetics has introduced a deep learning-based application on its Data-Driven Medicine (DDM) platform for detecting homologous recombination deficiency (HRD). The app combines identification of HRD-causing mutations with analysis of HRD-induced genomic instability across tumor genomes to inform cancer research.
NanoString Technologies GeoMx RNA Protocol on Bond Rx Research Staining Systems
NanoString Technologies has launched a new GeoMx RNA protocol on Bond Rx research staining systems, an open platform to develop customized protocols for immunohistochemistry and in situ hybridization with open reagents and detection options. According to the company, the improved RNA protocol is fully automated and offers whole-transcriptome profiling of formalin-fixed paraffin-embedded, fixed frozen, or fresh frozen tissues, improving the technology’s reproducibility and throughput while minimizing manual steps and reducing hands-on time. The new protocol creates a fully automated GeoMx Digital Spatial Profiler (DSP) workflow, which enables researchers to quickly see the biological complexity of heterogeneous tissues using GeoMx DSP’s combination of tissue morphological context and high-plex, whole-transcriptome RNA expression profiling from a single slide.
For more new products and services, please visit the New Products page on our website.